Search results
Results from the WOW.Com Content Network
Rituximab, sold under the brand name Rituxan among others, is a monoclonal antibody medication used to treat certain autoimmune diseases and types of cancer. [18] It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia (in children and adults, but not recommended in elderly patients), rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura ...
The most common side effects when used with other cancer medicines include peripheral neuropathy (nerve damage in the hands and feet), nausea, anemia (low red blood cell counts), neutropenia (low white blood cell counts), thrombocytopenia (low platelet counts), rash, tiredness, constipation, reduced appetite, diarrhea, and cough. [77]
Normal cells are more able than cancer cells to repair damage from chemotherapy drugs. This regimen can also be combined with the monoclonal antibody rituximab if the lymphoma is of B cell origin; this combination is called R-CHOP.
The treatment must be medically necessary. Doctors may recommend Rituxan for the treatment of conditions such as non-Hodgkin’s lymphoma , chronic lymphocytic leukemia , and rheumatoid arthritis .
Dave Coulier shared an update amid his ongoing treatment for stage 3 non-Hodgkin lymphoma, saying “it’s been a little bit of an adjustment” not having hair. “I'm feeling good.
The royal finished her chemotherapy treatment last year following a cancer diagnosis. ... And understanding that as a patient, yes, there are side effects around treatment, but actually there are ...
EPOCH is an intensive chemotherapy regimen intended for treatment of aggressive non-Hodgkin's lymphoma. [1] [2] It is often combined with rituximab. In this case it is called R-EPOCH or EPOCH-R. The R-EPOCH regimen consists of: Rituximab: an anti-CD20 monoclonal antibody, which has the ability to kill B cells, be they normal or malignant;
ICE in the context of chemotherapy is an acronym for one of the chemotherapy regimens, used in salvage treatment of relapsed or refractory non-Hodgkin's lymphoma and Hodgkin lymphoma. In case of CD20-positive B cell lymphoid malignancies the ICE regimen is often combined today with rituximab. This regimen is then called ICE-R or R-ICE or RICE.